Skip to content
Catalyst

knowcompoundsN-acetyl-L-cysteine

Specimen compound organic compoundPlate I

N-acetyl-L-cysteine

Nested hairline contours trace the electron density of one computed shape of N-acetyl-L-cysteine, teal at the edge warming to amber over the atoms.
fig. 1N-acetyl-L-cysteine · electron density · PubChem CID 12035, computed 3D conformer
Formula
C5H9NO3S
Molar mass
163.198 g/mol
PubChem CID
12035
InChIKey
PWKSKIMOESPYIA-BYPYZUCNSA-N

↑ raised 1 finding in 1 endpoint · ↓ lowered 3 in 3 · – no difference found 4 in 3

01 · the evidence, ordered

What the evidence says

Strong
1
Moderate
6
Limited
1
Very limited
0
Insufficient
0

How to read these marks

Fig. 2 N-acetyl-L-cysteine CHEBI:28939 6 endpoints 8 findings
×1.60
Labels
CompoundInspector

N-acetyl-L-cysteine

Most findings

  • All-cause mortality×3
  • Acute kidney injury incidence (any grade)×1
  • Clinical pregnancy rate×1
  • Hospital length of stay×1
  • Serum creatine kinase activity×1
  • Tumour necrosis factor alpha concentration×1

2 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. All-cause mortalitycontested
  2. Acute kidney injury incidence (any grade)
  3. Clinical pregnancy rate
  4. Hospital length of stay
  5. Serum creatine kinase activity
  6. Tumour necrosis factor alpha concentration
fig. 3 · 6 endpoints · 8 findingscontested · an endpoint whose findings disagree

02 · contested · 1 endpoint

Where the findings disagree

  1. 013 findings

    All-cause mortality

    ↓ lowered
    1
    – no difference found
    2

03 · findings

What N-acetyl-L-cysteine moved, and by how much

  • RR risk ratio · MD mean difference · OR odds ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

8 shown

  1. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedRR0.71[0.4 to 1.25]Evidence: Strongreplicated ×1Paper: PMID 310710812019
    Who
    Adults undergoing on-pump or off-pump cardiac surgery, 17 randomised trials pooled, NAC added to standard of care versus standard of care with or without placebo; routes pooled (intravenous, cardioplegia, oral) · n = 1,737
    Dose studied
    not reported

    Results from 17 RCTs including 1,737 patients yielded a non-statistically significant difference between NAC and SoC on the reduction of mortality (RR 0.71, 95% CI 0.40 to 1.25; events (NAC:20/870, SoC:33/867); I2 = 0%; p = 0.23).”

    Quoted verbatim from N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.meta-analysisPermalink
  2. Tumour necrosis factor alpha concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 396322672024
    Who
    Participants in pooled studies of NAC supplementation, concentrations after physical exertion
    Dose studied
    not reported

    However, we saw no significant effect of NAC on TNF-α, CK or GSSG concentrations.”

    Quoted verbatim from The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.meta-analysisPermalink
  3. Hospital length of stayMoved: lowersEffect, as reportedMD−3.84[−7.44 to −0.24]Evidence: ModeratePaper: PMID 427807692026
    Who
    Critically ill ICU patients with underlying respiratory disease; pooled across 2 randomized trials, NAC in addition to standard care versus placebo or regimens without NAC; reported in days
    Dose studied
    not reported

    However, pooled data from 2 studies assessing hospital LOS indicated a significantly shorter LOS in the NAC group than in the control group (MD = −3.84 days; 95% CI: −7.44 to −0.24; Table 3).”

    Quoted verbatim from Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.meta-analysisPermalink
  4. Acute kidney injury incidence (any grade)Moved: lowersEffect, as reportedRR0.51[0.31 to 0.82]Evidence: ModeratePaper: PMID 330672892020
    Who
    Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled
    Dose studied
    not reported

    Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”

    Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.meta-analysisPermalink
  5. Serum creatine kinase activityMoved: no difference foundEvidence: ModeratePaper: PMID 396322672024
    Who
    Participants in pooled studies of NAC supplementation, concentrations after physical exertion
    Dose studied
    not reported

    However, we saw no significant effect of NAC on TNF-α, CK or GSSG concentrations.”

    Quoted verbatim from The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.meta-analysisPermalink
  6. Clinical pregnancy rateMoved: raisesEvidence: ModeratePaper: PMID 394152422024
    Who
    Women aged 21 to 38 with polycystic ovary syndrome and anovulation or oligo-ovulation undergoing letrozole plus urinary FSH ovulation induction (up to three cycles) in both arms; pragmatic open-label trial with blinded outcome assessors and a no-NAC control group (human arm only)
    Dose studied
    1.8 g/day oral (0.6 g three times daily) from day 2 to 4 of the cycle for five consecutive days, each induction cycle

    In the comparison of clinical pregnancy rates, both per OI cycle and cumulative per patient, the rates in the NAC group were significantly greater than those in the control group (30.99% vs. 23.30%, p = 0.040; and 77.88% vs. 58.04%, p = 0.001, respectively).”

    Quoted verbatim from N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome.RCTPermalink
  7. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedOR0.85[0.43 to 1.68]Evidence: Moderatereplicated ×1Paper: PMID 347326002022
    Who
    Adults undergoing cardiac surgery, eight randomised trials pooled, NAC versus placebo; in-hospital mortality horizon
    Dose studied
    not reported

    Meta-analytic estimates for in-hospital mortality showed that there was no statistically significant difference between patients treated with NAC and without, as shown in Supplemental Fig. 6 (OR: 0.85, 95% CI: 0.43–1.68).”

    Quoted verbatim from N-Acetylcysteine's Renoprotective Effect in Cardiac Surgery: A Systematic Review and Meta-Analysis.meta-analysisPermalink
  8. All-cause mortalitycontestedMoved: lowersEffect, as reportedRR0.37[0.17 to 0.79]Evidence: LimitedPaper: PMID 330672892020
    Who
    Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled; in-hospital mortality horizon
    Dose studied
    not reported

    Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”

    Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.meta-analysisPermalink

No dose is advised.

  • RR risk ratio · MD mean difference · OR odds ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

04 · identity

Structure

fig. 4N-acetyl-L-cysteine · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CC(=O)N[C@@H](CS)C(=O)O

05 · figures · 1 plate

Plates

  • A dial of hairlines, each a peak of N-acetyl-L-cysteine's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 5N-acetyl-L-cysteine · MS2 [M-H]- LC-ESI-ITFT negative · MassBank MSBNK-mFam-MC20_000175 (Stacey N Reinke, CC BY)

06 · reach

What it touches on the way

1 entity · assembled from reference reactions

  1. NAGSProtein11 paths · 11 endpointsinferred

07 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
201 ProteinSLC7A11, NAGSinferred, one hop from N-acetyl-L-cysteine
Reactions · Rhea
13reactions
2Reference statements

What the reference databases state

Evidence key

Statements

2 statements

Sources: Human-GEM, Rhea

13Reactions

08 · on the label · 1,558 products

Labelled products

Source: NIH DSLD · Ingredient: N-acetyl-L-cysteine · 1,558 products · Declared amount per serving (the first 1,000 shown): 0.25–1,800 mg

794 labels of the first 1,000 shown state an amount206 do not

  • 'Merica LabzGuts 'N Glory Gut Punch600 mgper 5.1 gDSLD:213374
  • 1MDImmunityMD+600 mgper 1 capsuleDSLD:246766
  • 1st PhormLiver Detox1,200 mgper 5 capsulesDSLD:242910
  • 1st PhormRemedyamount not statedper 5 capsulesDSLD:242989
  • 20S20 NutritionSuper Natural PCTamount not statedper 2 capsulesDSLD:286854
  • 4LifeFibro AMJ Day Time Formulaamount not statedper 3 capsulesDSLD:249650
  • 4LifeReCallamount not statedper 3 capsulesDSLD:248412
  • 4LifeSleepRite AMJamount not statedper 2 capsulesDSLD:249818
  • 8WeeksOutNRF2Guard 1125 mgamount not statedper 2 capsulesDSLD:228521
  • 8WeeksOutTestogenXamount not statedper 2 capsulesDSLD:228469
  • AB American BiologicsOxy-5000 Forte10 mgper 2 tabletsDSLD:20260
  • AB American BiologicsOxy-5000 Forte10 mgper 2 tabletsDSLD:20268
Show the remaining 1,546Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

09 · the record

Sources

894

papers screened for N-acetyl-L-cysteine

admitted
8
read and discarded
234
not read yet
652

The screening record, every paper and why

Sources cited

6 papers · 8 findings

2 admitted at screening, no finding yet

Show every paper citedHide the papers cited
920Endpoints measured, not recorded as findingsEvery row, on one page
710Papers indexed under N-acetyl-L-cysteine